Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Aug 12;10(8):1076.
doi: 10.3390/nu10081076.

The Vitamin K Metabolome in Chronic Kidney Disease

Mandy E Turner  1 , Michael A Adams  2 , Rachel M Holden  3   4
Affiliations
Review

The Vitamin K Metabolome in Chronic Kidney Disease

Mandy E Turner et al. Nutrients. .

Abstract

The purpose of this review is to summarize the research to date on the impact of chronic kidney disease (CKD) on the vitamin K metabolome. Vitamin K-dependent proteins contribute to cardiovascular disease (CVD) prevention via the prevention of ectopic mineralization. Sub-clinical vitamin K deficiency is common in CKD patients, and evidence suggests that it may contribute to the CVD burden in this population. Research from animal models suggests that CKD alters tissue measures of the two predominant forms of vitamin K: KI and MK-4. The expression and/or activity of enzymes that regulate the recycling of vitamin K and the carboxylation of vitamin K-dependent proteins also appear to be altered in CKD. Evidence suggests that statins, a common pharmaceutical prescribed to CKD patients to prevent cardiovascular events, may impact the metabolism of vitamin K and therefore contribute to its relative inefficiency at preventing CVD in this population as kidney disease progresses. Human research on the tissue vitamin K metabolome in CKD patients is lacking.

Keywords: chronic kidney disease; menaquinone-4; phylloquinone; vitamin K; vitamin K dependent proteins.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Provenzano R. The economics of late-stage chronic kidney disease. Adv. Chronic Kidney Dis. 2016;23:222–226. doi: 10.1053/j.ackd.2015.12.002. - DOI - PubMed
    1. Go A.S. Cardiovascular disease consequences of CKD. Semin. Nephrol. 2016;36:293–304. doi: 10.1016/j.semnephrol.2016.05.006. - DOI - PubMed
    1. Cranenburg E.C.M., Schurgers L.J., Uiterwijk H.H., Beulens J.W.J., Dalmeijer G.W., Westerhuis R., Magdeleyns E.J., Herfs M., Vermeer C., Laverman G.D. Vitamin K intake and status are low in hemodialysis patients. Kidney Int. 2012;82:605–610. doi: 10.1038/ki.2012.191. - DOI - PubMed
    1. Elliott M.J., Booth S.L., Hopman W.M., Holden R.M. Assessment of potential biomarkers of subclinical vitamin K deficiency in patients with end-stage kidney disease. Can. J. Kidney Heal. Dis. 2014;1:13. doi: 10.1186/2054-3581-1-13. - DOI - PMC - PubMed
    1. Holden R.M., Morton A.R., Garland J.S., Pavlov A., Day A.G., Booth S.L. Vitamins K and D status in stages 3–5 chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2010;5:590–597. doi: 10.2215/CJN.06420909. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources